ArticleACS medicinal chemistry letters2013
Pharmacological activity of retinoic acid receptor alpha-selective antagonists
Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Development of a Second-Generation RARα Selective Antagonist as an Orally Bioavailable, Effective, Safe, and Reversible Male Contraceptive.Journal of medicinal chemistry · 2026Article
- From Discovery to Clinical Trial: YCT-529, an Oral NonHormonal Male Contraceptive Targeting the Retinoic Acid Receptor Alpha.Journal of medicinal chemistry · 2026Article
- Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review.Contraception · 2025Review
- Non-hormonal Contraception: Current and Emerging Targets.Advances in experimental medicine and biology · 2025Review
- The state of the art in secondary pharmacology and its impact on the safety of new medicines.Nature reviews. Drug discovery · 2024Review
- Review
- Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception.European journal of medicinal chemistry · 2023Article
- Male contraception: narrative review of ongoing research.Basic and clinical andrology · 2023Review
- Investigation of selective retinoic acid receptor alpha antagonist ER-50891 and related analogs for male contraception.Archiv der Pharmazie · 2023Article
- Gut microbiota-derived lipid metabolites facilitate regulatory T cell differentiation.Scientific reports · 2023Article
- Emerging approaches to male contraception.Fertility and sterility · 2021Review
- Filamentous actin disorganization and absence of apical ectoplasmic specialization disassembly during spermiation upon interference with retinoid signaling†.Biology of reproduction · 2020Article
- Retinoic acid receptor antagonists for male contraception: current status†.Biology of reproduction · 2020Review
- Development of Novel Male Contraceptives.Clinical and translational science · 2020Review
- The future of male contraception: a fertile ground.Translational andrology and urology · 2018Review
- Beyond the Condom: Frontiers in Male Contraception.Seminars in reproductive medicine · 2016Review
- Article
- Non-hormonal male contraception: A review and development of an Eppin based contraceptive.Pharmacology & therapeutics · 2016Review
- Male contraception.Best practice & research. Clinical obstetrics & gynaecology · 2014Review
- Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options.Therapeutic advances in reproductive healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Oral administration of a retinoic acid receptor (RAR) pan-antagonist reversibly inhibits spermatogenesis. Given the importance of RARα in regulating spermatogenesis, we identified two RARα-selective antagonists by transactivation and transactivation competition assays and asked whether they effectively inhibit spermatogenesis. Although these two antagonists were potent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.